Zacks Research Issues Optimistic Outlook for STERIS Earnings

STERIS plc (NYSE:STE) – Analysts at Zacks Research increased their Q3 2025 earnings estimates for shares of STERIS in a research report issued on Tuesday, January 21st. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $2.31 per share for the quarter, up from their previous estimate of $2.30. The consensus estimate for STERIS’s current full-year earnings is $9.11 per share. Zacks Research also issued estimates for STERIS’s FY2025 earnings at $9.08 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.54 EPS, Q4 2026 earnings at $2.81 EPS, FY2026 earnings at $9.99 EPS, Q1 2027 earnings at $2.48 EPS, Q2 2027 earnings at $2.59 EPS, Q3 2027 earnings at $2.63 EPS and FY2027 earnings at $10.35 EPS.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The firm had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the prior year, the company posted $2.03 earnings per share. The business’s revenue for the quarter was up 7.3% on a year-over-year basis.

Several other equities research analysts have also recently commented on STE. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Monday, November 18th. Stephens restated an “overweight” rating and set a $260.00 target price on shares of STERIS in a research note on Thursday, November 7th. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Finally, Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $262.50.

STERIS Stock Performance

Shares of STE opened at $216.88 on Thursday. The company has a market cap of $21.41 billion, a price-to-earnings ratio of 49.52 and a beta of 0.84. The business’s fifty day simple moving average is $211.46 and its two-hundred day simple moving average is $224.63. STERIS has a 12 month low of $197.82 and a 12 month high of $248.24. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.05%. The ex-dividend date was Tuesday, November 19th. STERIS’s dividend payout ratio is presently 52.05%.

Insider Activity

In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.14% of the company’s stock.

Institutional Investors Weigh In On STERIS

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its stake in shares of STERIS by 171.2% in the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock worth $191,370,000 after purchasing an additional 529,308 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in STERIS by 7,418.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 309,771 shares of the medical equipment provider’s stock worth $75,132,000 after buying an additional 305,651 shares during the period. Boston Trust Walden Corp increased its stake in STERIS by 400.4% in the 4th quarter. Boston Trust Walden Corp now owns 224,741 shares of the medical equipment provider’s stock worth $46,198,000 after buying an additional 179,829 shares in the last quarter. Swedbank AB purchased a new stake in STERIS in the 3rd quarter worth $28,251,000. Finally, Benjamin Edwards Inc. raised its holdings in STERIS by 2,123.2% during the third quarter. Benjamin Edwards Inc. now owns 113,672 shares of the medical equipment provider’s stock valued at $27,574,000 after acquiring an additional 108,559 shares during the period. Institutional investors own 94.69% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.